Recent Quotes (30 days)

You have no recent quotes
chg | %

Easton Pharmaceuticals Inc  

(Public, OTCMKTS:EAPH)   Watch this stock  
Find more results for EAPH
0.0000 (0.00%)
Oct 20 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range     -
52 week 0.01 - 0.06
Open     -
Vol / Avg. 0.00/1.48M
Mkt cap 19.59M
P/E     -
Div/yield     -
EPS 0.00
Shares 932.73M
Beta -19.07
Inst. own 0%

Key stats and ratios

Q2 (Jun '13) 2012
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -36.35% -29.33%
Return on average equity -239.86% -132.63%
Employees 5 -
CDP Score - -


265 Rimrock Rd Suite 200
+1-416-6190291 (Phone)
+1-416-6461000 (Fax)

Website links


Easton Pharmaceuticals, Inc. is a development-stage company engaged in various pharmaceutical sectors and others industries. The Company has a transdermal delivery technology (Viorra Delivery Matrix or VDM), which is incorporated in a line of therapeutic over-the-counter (OTC) products. The Company owns topically-delivered drugs and therapeutic/cosmetic healthcare products focused on cancer and other health problems geared towards female sexual dysfunction, wound healing, pain, motion sickness and other conditions. The Company's products are in various stages of commercialization. The Company's products include Nauseasol, which is a motion sickness gel; Skin Renou HA, which is an anti-aging wrinkle cream; Kenestrin Gel, which is a is a pain relief gel; Viorra, which serves as an aid to the relief of female sexual arousal disorder (FSAD); XILIVE, which is an early-stage cancer drug, and FSAD) drug, which includes a water-based complex polymer matrix.

Officers and directors

John Adams President, Chief Executive Officer
Age: 53
Walter Folinski Chief Financial Officer
Neil Mellor Chief Operating Officer
Jack Barkin M.D. Senior Vice President, Chief Medical Officer
Susan Whyte Vice President - Marketing
John Mitchell Vice President - Business Development